Stock comparison
AbbVie
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABBV
AbbVie
Market cap
$371.72B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABBV | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 69B | LMAT |
| Benjamin Graham | 80A | 81A | LMAT |
| Philip Fisher | 53C | 73B | LMAT |
| Peter Lynch | 22F | 59C | LMAT |
| Joel Greenblatt | 33F | 48D | LMAT |
| Charlie Munger | 60C | 60C | Tie |
| Terry Smith | 57C | 61C | LMAT |
Side-by-side metrics
| Metric | ABBV | LMAT |
|---|---|---|
| Market cap | $371.72B | $2.32B |
| P/E (TTM) | 102.6x | 37.1x |
| EV/EBIT | 21.7x | 36.6x |
| ROIC (TTM) | 10.29% | 9.43% |
| Gross margin | 73.46% | 72.39% |
| Net margin | 5.79% | 24.35% |
| Revenue CAGR 5y | 2.14% | 12.75% |
| EPS CAGR 5y | -22.23% | 19.04% |
| Debt / Equity | 2.6x | 0.5x |
| Dividend yield | 3.2% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABBV leads on
- Market cap$371.72Bvs $2.32B+99%
- Dividend yield3.2%vs 0.84%+74%
- EV/EBIT21.7xvs 36.6x+41%
- ROIC (TTM)10.29%vs 9.43%+8%
LMAT leads on
- EPS CAGR 5y19.04%vs -22.23%+186%
- Revenue CAGR 5y12.75%vs 2.14%+83%
- Debt / Equity0.5xvs 2.6x+82%
- Net margin24.35%vs 5.79%+76%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.